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through the PI3K/Akt/mTOR pathway
Tzu-Shao Yeh1, Cheng-Chen Hsu2†, Suh-Ching Yang1†, Mei-Chich Hsu3,4* and Jen-Fang Liu1,5,6*Abstract
Background: Angelica Sinensis (AS), a folk medicine, has long been used in ergogenic aids for athletes, but there is
little scientific evidence supporting its effects. We investigated whether AS induces hypertrophy in myotubes through
the phosphatidylinositol 3-kinase (PI3K)/Akt (also termed PKB)/mammalian target of the rapamycin (mTOR) pathway.
Methods: An in vitro experiment investigating the induction of hypertrophy in myotubes was conducted. To
investigate whether AS promoted the hypertrophy of myotubes, an established in vitro model of myotube
hypertrophy with and without AS was used and examined using microscopic images. The role of the PI3K/Akt/mTOR
signaling pathway in AS-induced myotube hypertrophy was evaluated. Two inhibitors, wortmannin (an inhibitor of
PI3K) and rapamycin (an inhibitor of mTOR), were used.
Result: The results revealed that the myotube diameters in the AS-treated group were significantly larger than those in
the untreated control group (P < 0.05). Wortmannin and rapamycin inhibited AS-induced hypertrophy. Furthermore, AS
increased Akt and mTOR phosphorylation through the PI3K pathway and induced myotube hypertrophy.
Conclusion: The results confirmed that AS induces hypertrophy in myotubes through the PI3K/Akt/mTOR pathway.
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Muscle mass is a primary determinant of muscle strength,
and is strongly associated with the performance of activ-
ities of daily living and the level of independence of the
elderly [1-3]. The phosphatidylinositol 3-kinase (PI3K)/
Akt (also termed PKB)/mammalian target of rapamycin
(mTOR) pathway is recognized as a possible mechanism
that regulates muscle mass [4-6]. In mammals, skeletal
muscle hypertrophy occurs as a result of an increased
size, instead of increased number, of preexisting skeletal
muscle fibers [7,8]. The effects of this pathway on skeletal
muscle are exhibited most prominently downstream of
insulin-like growth factor 1 (IGF-1) signaling. The prohy-
pertrophic activity of IGF-1 predominantly results from
activation of the PI3K/Akt/mTOR signaling pathway [9].
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unless otherwise stated.the induction of muscle atrophy F box and muscle RING-
finger protein 1 ubiquitin-ligases by using forkhead tran-
scription factor FOXO1 (also called “forkhead”), resulting
in the prevention of muscle atrophy [10,11]. Furthermore,
activating Akt is sufficient to prevent muscle atrophy [12],
and the kinase activity of Akt is essential for IGF-1-
induced hypertrophy [13]. The aforementioned findings
imply that the PI3K/Akt/mTOR pathway plays a pivotal
role in muscle hypertrophy and atrophy.
The C2C12 cell line, a myoblast cell line derived from
murine satellite cells, is used extensively as an in vitro
model to study both muscle differentiation and hyper-
trophy [14]. The withdrawal of serum from C2C12 myo-
blasts leads them to exit the cell cycle and fuse into
myotubes. C2C12 myotubes have been used in in vitro
models to study IGF-1 mediated hypertrophic signaling
pathways in skeletal muscle [9,15,16]. PI3K/Akt/mTOR
activation downstream of IGF-1 can induce hypertrophy
both in C2C12 cells in vitro [13] as well as in skeletal
muscle in vivo [12]. Thus, C2C12 myotubes provide a
useful, well-characterized, in vitro modelling system re-
garding the induction of hypertrophy in myotubes.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ergogenic aids to enhance athletic performance. The
dried root of Angelica Sinensis (AS) is widely used in
traditional Chinese medicine to “nourish one’s vitality
and enrich blood,” which means increasing the stamina
of weak patients and improving their strength. The
main chemical constituents of AS roots are ferulic acid,
ligustilide, angelicide, brefeldin A, butylidenephthalide,
butyphthalide, succinic acid, nicotinic acid, uracil, and
adenine [17]. The constituents most often associated
with the pharmacological activities of AS roots are feru-
lic acid and ligustilide (predominantly the Z-isomer).
Ferulic acid can inhibit platelet aggregation and sero-
tonin release, and ligustilide exhibits significant anti-
asthmatic and spasmolytic activities [17]. The levels of
these 2 constituents are typically used as chemical
markers for the quality control of AS roots [18,19].
Some of these roots are thought to exhibit proliferous
properties, whereas others might exhibit myogenesis ef-
fects. Ferulic acid, an active compound derived from
AS, can stimulate cell proliferation through Akt signaling
[20]. Polysaccharides in AS roots can promote the prolif-
eration and differentiation of hematopoietic stem and pro-
genitor cells and megakaryocytic lineages through the
PI3K/Akt pathway [21]. However, whether AS actually in-
duces hypertrophy in myotubes is unknown. Therefore,
we investigated whether AS induces hypertrophy in myo-
tubes through the PI3K/Akt/mTOR pathway. An in vitro




Mouse skeletal muscle cells, C2C12 myoblasts, were
purchased from the Bioresource Collection and Research
Center (Food Industry Research and Development Institute,
Hsinchu, Taiwan). Cells were maintained in 90% Dulbecco’s
modified Eagle’s medium (DMEM; 11965; Gibco, Invitro-
gen, Carlsbad, CA, USA), supplemented with 10% fetal
bovine serum (10437; Gibco, Invitrogen, Carlsbad, CA,
USA) and 1% penicillin-streptomycin-amphotericin B
(P/S/A; Biological industries, Kibbutz, Beit HaEmek,
Israel) at 37°C in a 5% CO2 atmosphere. Differentiation
was induced by changing the medium to DMEM con-
taining 2% horse serum (HS) and 1% P/S/A when the
cells attained 90% confluence [9,22]. The myotubes ma-
tured to striated cells by the fifth day after sowing, and the
cultures were used for experiments as described previously
[23]. The myotubes were assigned to 3 groups to investi-
gate the effects of AS on myotubes: (1) non-AS supple-
ment (normal growth medium: 2%HS/DMEM; NON);
(2) IGF-1 supplement (10 ng/mL, in 2% HS/DMEM;
as a positive control; IGF-1); and (3) AS supplement
(10 ng/mL, in 2% HS/DMEM; AS).Herbal and chemical reagents
The herbal and chemical reagent stocks used were as
follows: AS (10 mg/mL; HerBesta, ITS-TW, Taipei,
Taiwan), wortmannin (1 μM; inhibitor of PI3K, W1628,
Sigma, St. Louis, MO, USA), rapamycin (100 ng/mL; in-
hibitor of mTOR, R0395, Sigma, St. Louis, MO, USA),
and IGF-1 (100 ng/mL, I8779, Sigma, St. Louis, MO,
USA). The AS and chemicals were dissolved separately
in phosphate-buffered saline ( 137 mM NaCl, 8.10 mM
Na2HPO4, 2.68 mM KCl, 1.47 mM KH2PO4, pH 7.40).
The stocks were stored in aliquots at −20°C. Regarding
treatment, the stocks were diluted in the medium and
added directly to the cultured cells according to the fol-
lowing final concentrations: AS (1, 10, 102, 103, 104, 105,
106 ng/mL in 2% HS/DMEM), wortmannin (100 nM in
DMEM), rapamycin (10 ng/mL in DMEM), and IGF-1
(10 ng/mL in 2% HS/DMEM; as a positive control for
the activated PI3K/Akt/mTOR pathway).
Assessment of Angelica Sinensis cytotoxicity in myotubes
through an XTT assay
C2C12 cells were cultivated in a flat 96-well plate at a
density of 5 × 103 cells per well, and incubated for 5 d to
permit the maturation of the myotubes into striated
cells. AS was added to the myotubes at various concentra-
tions (1, 10, 102, 103, 104, 105, 106 ng/mL) after the
myotubes matured. After 24, 48, and 72 h, an XTT (2, 3-
Bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-
5-carboxanilide inner salt) reagent (Biological industries,
Kibbutz, Beit HaEmek, Israel) was added to each well
according to the manufacturer’s instructions. After 2 h
in the culture, cell viability was determined by measur-
ing the absorbance at 490 nm, using a 550 BioRad plate
reader (Bio-Rad, Hertfordshire, UK). Dose and time
course experiments were performed in quadruplicate.
Myotube hypertrophy based on measurement of
myotube diameter
The C2C12 cells were seeded at a density of 2 × 105 cells
in 6-well plates (BD Biosciences, Sparks, MD, USA). The
myotubes were matured after 5 d, and used in the exper-
iments. To conduct the AS-induced myotube hyper-
trophy experiment, the myotubes were treated with AS
(10 ng/mL, AS in 2% HS/DMEM) or fresh growth
medium (DMEM containing 2% HS; NON) and incubated
for 72 h; the myotube diameters were then determined.
To determine the effects of inhibitors on AS-induced
hypertrophy, the myotubes were treated with or without
inhibitors (wortmannin or rapamycin) 30 min before the
trials. The culture medium was replaced with IGF-1
(10 ng/mL, in 2% HS/DMEM), AS (10 ng/mL, in 2% HS/
DMEM), or fresh growth medium (2% HS/DMEM;
NON). The trials were conducted at 37°C in an atmos-
phere of 5% CO2. After 72 h of incubation, the myotube
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formed in triplicate.
The myotube diameters were determined using a
light microscope (Olympus CKX41, with a 20× object-
ive lens; Olympus, Tokyo, Japan) with a digital camera
system (Olympus C7070; Olympus, Tokyo, Japan) and
MediaCybernetic Image-Pro Plus software (MediaCy-
bernetic, Bethesda, MD, USA). Each group was cul-
tured in 3 wells, and each well was evenly divided into
9 square grid sections. Three images for each section
were captured. At least 10 myotubes per image were
measured. Three short-axis measurements were taken
along the length of a given myotube diameter and the
average was calculated.
Western blotting
The myotubes were treated with AS (10 ng/mL) at vari-
ous time points, and the time point that exhibited the
highest protein expression of phosphospecific Akt and
mTOR was identified using western blotting. According
to the time point that exhibited the highest level phos-
phospecific of Akt and mTOR, the myotubes were
treated with AS, and 1 μM wortmannin, an inhibitor of
PI3K, was added for 30 min to break the PI3K/Akt/
mTOR pathway. After incubation, the myotubes from
the cell culture plate were scraped into an eppendorf
tube to analyze the protein levels of phosphorylated Akt
on Ser473 (p-Akt) and mTOR on Ser2448 (p-mTOR) (Cell
Signaling Technology, Beverly, MA, USA). This analysis
was conducted using western blotting.
Cells were lysed using a CelLytic Extraction Kit (Sigma-
Aldrich, St. Louis, MO, USA) with 1% phosphatase in-
hibitor cocktail 3 (Sigma-Aldrich, St. Louis, MO, USA).
Quantification was performed using a protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). Samples
containing 50 μg of total protein were separated using
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis for 150 min at 120 V by applying 8% gradient gels on
a Criterion electrophoresis cell (Bio-Rad Laboratories,
Richmond, CA, USA).
Proteins were transferred to a polyvinylidene fluoride
membrane (PALL Gelman Laboratory, Taipei, Taiwan) at
a 100-mA constant current for 10 h on ice at 4°C. The
membrane was blocked in a tris-buffered saline (TBS)
solution containing 0.1% Tween 20 (TBS-T) and 5%
nonfat dry milk for 1 h and then incubated overnight at
4°C, using commercially available rabbit polyclonal pri-
mary phosphospecific antibodies. These antibodies rec-
ognized the phosphorylated Akt on Ser473, mTOR on
Ser2448 (Cell Signaling Technology, Beverly, MA, USA),
and β-actin (Sigma-Aldrich, St. Louis, MO, USA).
All antibodies were diluted to a 1:500 ratio in TBS-T
containing 5% nonfat dry milk (except β-actin, which
was diluted to a ratio of 1:10 000). The membranes werethen washed in TBS-T, incubated using a secondary
antibody (horseradish peroxidase-conjugated antirabbit
IgG; Sigma-Aldrich, St. Louis, MO, USA), and diluted to
a ratio of 1:16 000 in TBS-T with 5% milk for 1 h,
followed by washing in TBS-T. Phosphorylated proteins
were visualized using enhanced chemiluminescence accord-
ing to the manufacturer’s protocols (Pierce Biotechnology,
Rockford, IL, USA) and quantified using MediaCybernetic
Image-Pro Plus software (MediaCybernetic, Bethesda,
MD, USA).
The membranes described above were incubated in
Restore Western Blot Stripping Buffer (Pierce Biotechnology,
Rockford, IL, USA) for 30 min and reprobed using the
appropriate antibodies for detecting the total expression
levels of Akt, mTOR (rabbit monoclonal primary anti-
body) (Cell Signaling Technology, Beverly, MA, USA), and
β-actin by using western blot analysis. All experiments
were performed in triplicate.
Statistical analysis
All values were expressed as the mean ± standard devi-
ation (SD). The myotube diameters of the 2 treatments
(AS vs. NON) were compared using a Student’s t test.
The phosphorylation levels of Akt or mTOR at various
treatment time points were analyzed using a one-way
analysis of variance (ANOVA). Group and treatment effect
data were analyzed using a 2-way ANOVA combined with
Scheffe posthoc analysis. Significance was determined at
the P < 0.05 level. All tests were performed using Statistical
Package for Social Science (SPSS, Chicago, IL, USA) soft-
ware Version 14.0 for Microsoft Windows.
Detection of ferulic acid in Angelica Sinensis by using high
performance liquid chromatography
To confirm the quality of the AS, we detected its main
chemical constituents. The amount of ferulic acid in the
AS was analyzed using a high performance liquid chroma-
tographic method [24]. Quantification was accomplished
using a comparison of the peak areas of the sample with
those of the reference standard. The amount of ferulic
acid in the AS was 0.61 mg/g (Additional file 1: Figure S1
and S2).
Results
Concentration and time effects of Angelica Sinensis on the
viability of myotubes
The viability of cells in the group without AS treatment
was expressed as 100%. As shown in Table 1, at 24 h,
the cell viability of myotubes decreased by 9%, 16%, and
26% when exposed to 104, 105, and 106 ng/mL of AS, re-
spectively, compared with the cells in the untreated con-
trol group. At 48 h, the cell viability of the myotubes
decreased by 9%, 25%, and 31% when exposed to 104,
105, and 106 ng/mL of AS, respectively, compared with
Table 1 Effect of Angelica Sinensis on viability of myotubes (%)
Concentration of Angelica Sinensis treatment (ng/mL)
Control 1 10 102 103 104 105 106
24 h 100.00 ± 3.53 99.45 ± 4.09 99.89 ± 5.64 98.18 ± 4.52 93.94 ± 6.59 91.24 ± 4.34 83.62 ± 5.07* 74.41 ± 5.88*
48 h 100.00 ± 3.42 100.15 ± 5.34 100.04 ± 5.56 100.13 ± 5.75 93.49 ± 4.44 91.22 ± 4.09 75.08 ± 5.15* 68.82 ± 4.65*
72 h 100.00 ± 3.75 98.56 ± 3.49 99.42 ± 5.21 99.17 ± 4.86 91.31 ± 3.92 90.64 ± 3.59 74.93 ± 5.26* 68.45 ± 4.53*
Values are mean ± SD (n = 4). Data were analyzed with one-way ANOVA with dose factors. *Significantly different compared with the control at the same time of
culture (Scheffe’s post hoc analysis, P < 0.05).
Yeh et al. BMC Complementary and Alternative Medicine 2014, 14:144 Page 4 of 9
http://www.biomedcentral.com/1472-6882/14/144the cells in the untreated control group. At 72 h, the cell
viability of the myotubes decreased by 9%, 25%, and 32%
when exposed to 104, 105, and 106 ng/mL of AS, respect-
ively, compared with the cells in the untreated control
group. The cell viability at concentrations of 105 and
106 ng/mL of AS was significantly decreased compared
with the control group after the same period of culturing
(P < 0.05). The results indicated that AS was not harmful
to myotubes at concentrations of 1, 10, or 102 ng/mL.
Therefore, an AS concentration of 10 ng/mL was used
to induce hypertrophy in the experiment.
Myotube hypertrophy induced by Angelica Sinensis
To determine whether AS is functionally critical for
myotube hypertrophy, the influence of AS (10 ng/mL)
on myotube thickness was examined. After 72 h of incu-
bation, highly thickened myotubes were observed in the
AS-treated group. The myotube diameter of 2 groupsFigure 1 Angelica Sinensis (AS) induced myotube hypertrophy after 7
microscope images. Right panel shows a representative myotubes of imag
SD. (A) NON, non- Angelica Sinensis supplements, Dulbecco’s modified Eag
10 ng/mL of AS in 2% HS/DMEM, n = 91; n-value represented the myotube
significantly enlarged in AS group. Data were analyzed with the Student’s t(NON and AS) exhibited normal distribution. The result
indicated that the average myotube diameter in the AS
group increased 1.34 ± 0.13 fold compared with the
NON group (P < 0.05, Figure 1). This clearly revealed
that AS induced myotube hypertrophy.
Involvement of the PI3K/Akt/mTOR pathway in Angelica
Sinensis-induced myotube hypertrophy
To examine the role of the PI3K/Akt/mTOR signaling
pathway in AS-induced myotube hypertrophy, pharma-
cologic experiments were conducted using inhibitors
that interfered with this pathway. IGF-1 stimulation that
activated the pathway was used as a positive control.
The PI3K inhibitor, wortmannin, reduced the diameters of
AS-treated myotubes by 25% (P < 0.05, Figure 2A, AS),
and the diameters of the positive controls by approxi-
mately 30% (P < 0.05, Figure 2A, IGF-1). The mTOR
inhibitor, rapamycin, behaved similarly to wortmannin2 h treatment. Histograms of myotube diameters derived from
e. Scale bar = 50 μm. Quantification of mean myotube diameter (M) ±
le’s medium (DMEM) containing 2% horse serum (HS), n = 107; (B) AS,
numbers from image. The mean of myotube diameters (M) was
-test. Statistical significance: *P < 0.05 vs. NON.
Figure 2 Effects of inhibitors on Angelica Sinensis (AS)-induced
hypertrophy after 72 h treatment. C2C12 myotubes were treated
for 72 h with: 100 nM wortmannin in DMEM, an inhibitor of PI3K
(A); 10 ng/mL rapamycin in DMEM, an inhibitor of mTOR (B). The
vertical axes indicated relative myotube diameter normalized to the
mean diameter of non-AS supplements (error bars: SD). Black bars
represented myotubes without inhibitors, and white bars were
myotubes with inhibitors, respectively. NON, non-AS supplements,
2% HS/DMEM; IGF-1, Insulin growth factor 1 stimulation, 10 ng/mL
of IGF-1 in 2% HS/DMEM; AS, Angelica Sinensis treatment, 10 ng/mL
of AS in 2% HS/DMEM. (NON, n = 103; IGF-1, n = 92; AS, n = 91; n-value
represented the myotube numbers from image). Data were analyzed
with two-way ANOVA. *Significantly different compared with the NON
without inhibitor: wortmannin (A) and rapamycin (B) (Scheffe’s
post hoc analysis, P < 0.05). #Significant inhibitor effect in the same
group (Scheffe’s post hoc analysis, P < 0.05).
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mTOR pathway played a crucial role in AS-induced myo-
tube hypertrophy.
Akt phosphorylation induced by Angelica Sinensis
Following the aforementioned indication of the role of
the PI3K/Akt/mTOR pathway in AS-induced myotube
hypertrophy, we investigated whether Akt phosphoryl-
ation was promoted by AS. First, a time-course analysis
was performed using western blotting, which showed that
15 and 45 min of AS treatment significantly elevated the
Akt phosphorylation level (P < 0.05), as did IGF-1 stimula-
tion regarding the positive control (P < 0.05, Figure 3A).Second, further investigation showed that Akt phosphoryl-
ation induced by 15 min of AS treatment was significantly
reduced beyond the non-AS supplement’s level (P < 0.05,
Figure 3B), using wortmannin; essentially the same results
were obtained in the samples regarding Akt phosphoryl-
ation induced by 45 min of AS treatment (Figure 3C).
These data suggested that AS promoted Akt phosphoryl-
ation through the PI3K pathway, which was observed in
the case of IGF-1 stimulation.
Mamallian target of rapamycin phosphorylation induced
by Angelica Sinensis
The procedure for this experiment resembled the afore-
mentioned time-course analysis. Results showed that
30 min of AS treatment significantly elevated the mTOR
phosphorylation level (P < 0.05), as did IGF-1 stimulation
in the positive control group (P < 0.05, Figure 4A). How-
ever, a decrease was observed in the phosphorylation level
of mTOR between 5 and 30 min after the AS treatment of
the myotubes. The mTOR phosphorylation behaved
similarly to Akt phosphorylation, but more powerfully
expressed the hypertrophy signal in the AS-treated sam-
ple. Furthermore, the elevated phosphorylation induced
using AS treatment for 30 min was significantly reduced
using wortmannin compared with the non-AS supple-
mented group (P < 0.05, Figure 4B). The non-AS supple-
mented group exhibited a similar reaction. Additionally,
the wortmannin inhibition of phosphorylation levels was
not significantly different between the 2 groups. As shown
in Figures 3B and 4B, the AS-induced hypertrophy
through the PI3K/Akt/mTOR phosphorylation pathway
was completely inhibited using wortmannin; however, it
was unclear whether the hypertrophy was solely induced
by the PI3K/Akt/mTOR pathway. Nonetheless, after wort-
mannin inhibition the AS-induced phosphorylation was
significantly reduced. Therefore, PI3K undoubtedly played
a major role in hypertrophy.
Discussion
The primary finding of the present study was that AS in-
creased myotube hypertrophy through the PI3K/Akt/
mTOR pathway. According to a thorough review of rele-
vant research, this is the first study to demonstrate that
myotube hypertrophy induced by AS treatment occurs
through the PI3K/Akt/mTOR pathway, as does IGF-1-
induced hypertrophy. Furthermore, treatment with AS
increases the activation of the PI3K/Akt/mTOR pathway.
The PI3K/Akt/mTOR pathway was investigated to
understand the mechanism through which AS promotes
hypertrophy. Activating this pathway promotes skeletal
muscle hypertrophy and prevents muscle atrophy [25]
because the kinase activity of Akt is essential for IGF-1-
induced hypertrophy [13]. Akt is a serine-threonine pro-
tein kinase that can induce protein synthesis and block
Figure 3 Phosphorylation of Akt induced by Angelica Sinensis
(AS). (A) Upper panel showed a representative result of western
blot analysis of total- Akt (t-Akt) and phosphor-Akt (p-Akt) levels in
the myotubes treated with 10 ng/mL of IGF-1 in 2% HS/DMEM for
45 min, or AS (10 ng/mL of AS in 2% HS/DMEM) for 5 to 60 min.
(B) Akt phosphorylation level at 15 min in wortmannin-treated
myotubes. (C) Akt phosphorylation level at 45 min in wortmannin-
treated myotubes. p-Akt and t-Akt were normalized by individual
β-actin. The results of the densitometric analysis of the western blot
membranes [upper panels in (A), (B) and (C)] were depicted in the
lower panels as the ratio of p-Akt against the t-Akt signal (mean ±
SD, n = 3), respectively. Vertical axis represented relative p-Akt level
compared with pre-treated myotubes (A), or non-treated myotubes
(B) and (C). Data were analyzed with one-way ANOVA with time
factors in (A). Data were analyzed with two-way ANOVA with group
and inhibitor treat as factors in (B) and (C). *Significant time effect
compared with pre-treat in (A) (Scheffe’s post hoc analysis, P < 0.05).
*Significantly different compared with the NON without inhibitor
wortmannin in (B) and (C) (Scheffe’s post hoc analysis, P < 0.05).
#Significant inhibitor effect in the same group (Scheffe’s post hoc
analysis, P < 0.05).
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etal muscle atrophy [26]. No previous studies that exam-
ined AS have investigated the regulation of the PI3K/
Akt/mTOR pathway in myotube hypertrophy. Immuno-
blotting by using antibodies against activated or total
Akt and mTOR revealed that AS activated this pathway
in myotubes, which clarified AS’s hypertrophic effects on
myotubes.
Wortmannin, a specific inhibitor of PI3K, was used to
distinguish whether AS activated Akt through the clas-
sical PI3K pathway or through an alternative pathway.
Wortmannin attenuated Akt activation was induced
using AS, which demonstrated that Akt activation by
using AS is dependent on the PI3K pathway. In this
study, we observed that wortmannin inhibited hyper-
trophy that was promoted using AS, confirming that
PI3K-mediated Akt activation by using AS was necessary
to induce hypertrophy in myotubes.
Rapamycin is a pharmacologic agent that binds to
mTOR and inhibits its functioning [27]. In vitro, when ap-
plied to myotube cultures, rapamycin blocks activation of
p70S6K downstream of either activated Akt or IGF-1
stimulation [27,28]. In this study, we observed that rapa-
mycin inhibited the hypertrophy promoted using AS,
which confirmed that Akt-mediated mTOR activation by
using AS is necessary to induce hypertrophy in myotubes.
As shown in Figure 4, we observed that myotubes
treated with AS for 15 min or longer had significantly
increased levels of PI3K-mediated Akt activation on
Ser473 (P < 0.05) resulting in hypertrophy, and that acti-
vating Akt and its resulting downstream effects was trig-
gered by treatment with AS. AS is responsible for the
increase in the activation of mTOR phosphorylation at
Ser2448 observed 30 min after AS treatment (Figure 4A).
Figure 4 Phosphorylation of mTOR induced by Angelica Sinensis
(AS). (A) Upper panel showed a representative result of western blot
analysis of total (t-mTOR) and phosphor-mTOR (p-mTOR) levels in the
myotubes treated with 10 ng/mL of IGF-1 in 2% HS/DMEM for 45 min,
or AS (10 ng/mL of AS in 2% HS/DMEM) for 5 to 60 min. (B) mTOR
phosphorylation level at 30 min in wortmannin-treated myotubes.
p-mTOR and t-mTOR were normalized by individual β-actin. The results
of the densitometric analysis of the western blot membranes
[upper panels in (A) and (B)] were depicted in the lower panels as
the ratio of p-mTOR against the t-mTOR signal (mean ± SD, n = 3),
respectively. Vertical axis represented relative p-mTOR level compared
with pre-treated myotubes (A), or non-treated myotubes (B). Data
were analyzed with one-way ANOVA with time factors in (A). Data
were analyzed with two-way ANOVA with group and inhibitor treat
as factors in (B). *Significant time effect compared with pre-treat in
(A) (Scheffe’s post hoc analysis, P < 0.05). *Significantly different
compared with the NON without inhibitor wortmannin in (B)
(Scheffe’s post hoc analysis, P < 0.05). #Significant inhibitor effect
in the same group (Scheffe’s post hoc analysis, P < 0.05).
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tion of cellular metabolism and has been shown to induce
rapid skeletal muscle hypertrophy in vivo [29]. Phosphor-
ylation of Ser473 is required for maximal activation of Aktand it appears that Akt might have a relatively short acti-
vation period after nutritional stimulation is activated by
protein growth factors [30-32]. In this study, the protein
level of Akt phosphorylation was observed as early as
5 min after AS treatment and reached maximum protein
expression at 15 min. These results were consistent with
previous reports [30].
This study revealed that AS increased myotube diam-
eter and seemed to be mediated via the mTOR pathway.
Because 2% horse serum was used in all treatment media
throughout the study, the mechanism might have
resulted from the direct effect of AS on the mTOR path-
way or the enhanced mTOR pathway caused by facilita-
tion of the binding of IGF-1 to its receptor. However,
our results revealed that myotube diameter in the AS
group was significantly thickened compared with that of
the NON group, but not the IGF-1 group (Figure 2). Ac-
cording to our in vitro data, even if horse serum con-
tained IGF-1, AS-induced myotube hypertrophy did not
entirely enhance the mTOR pathway by facilitating the
binding of IGF-1 to its receptor (Figure 2). We suggest
that further study by using a serum free medium is re-
quired to investigate how AS activates the PI3K/Akt/
mTOR pathway.
mTOR is a 289 kDa serine-threonine kinase partially
downstream of Akt and is responsible for the complex in-
tegration of anabolic stimuli mediating cell growth [32].
Although AKT phosphorylated mTOR at 2 COOH-
terminal sites (Thr2446 and Ser2448) in vitro, Ser2448 was
the major phosphorylation site in insulin-stimulated
or -activated AKT-phosphorylating human skeletal muscle
cells [32,33]. Phosphorylation of mTOR at Ser2448 has
become a popular biomarker for the activation state of
skeletal muscle hypertrophy signaling pathways and
the activation status of mTOR [28,30,34]. A previous
study reported that mTOR is a direct substrate for the
Akt kinase and identified Ser2448 as the Akt target site
in mTOR [35]. In addition to the regulation of mTOR
by using the PI3K/Akt pathway, others have provided
evidence that the Ser2448 phosphorylation primarily re-
flects a feedback signal to mTOR from its downstream
target, p70S6 kinase (S6K1) [36]. Figure 4 shows that
30 min of AS treatment significantly elevated the
mTOR phosphorylation level at Ser2448. The negative
regulation of skeletal muscle hypertrophy through the
p70S6 pathway was a possible reason for the increased
phosphorylated mTOR at the Ser2448 site between 30
and 60 min that was observed. However, downstream
signaling factors were required to sustain AKT/mTOR
signaling. Our results suggested that, at least regarding
the cell types examined in this study, Ser2448 phos-
phorylation exhibited both direct and indirect reac-
tions by using AS stimulation and markers of Akt
activation.
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The results confirm that AS induces hypertrophy in
myotubes through the PI3K/Akt/mTOR pathway.
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